Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer
01 Agosto 2023 - 8:00AM
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancers, today announced the appointment of
Kimberly Freeman as Chief Strategy Officer. In this role, she will
support and implement Zentalis’ long-term portfolio strategy. Ms.
Freeman joins Zentalis with over 25 years of clinical development
and strategic leadership experience, including deep expertise in
oncology, particularly in gynecologic malignancies and the DNA
damage response (DDR) pathway.
“Kimberly brings an outstanding track record of building and
executing drug development and franchise strategies that will be
invaluable to Zentalis as we seek to capitalize on the significant
opportunity we see with azenosertib across a broad array of tumor
types,” said Dr. Kimberly Blackwell, Chief Executive Officer of
Zentalis. “We welcome her unique skill set, which is ideally suited
to helping us advance azenosertib to patients with ovarian and
uterine cancers, as well as expand to other Cyclin E1 positive
tumor types where patients typically face poor prognosis. Kimberly
has successfully driven multiple cancer programs from early
clinical development to FDA approval, led a billion-dollar product
franchise, and has a deep network in the gynecologic oncology
community.”
Prior to joining Zentalis, Ms. Freeman was Vice President, US
Head of DDR Franchise, Oncology at AstraZeneca. She was responsible
for overseeing the strategic direction and cross-functional efforts
for LYNPARZA® (olaparib) and other therapies targeting the DDR
pathway, which is an important hallmark in ovarian and other
cancers. Previously, she held various leadership roles at
biopharmaceutical companies including Adaptimmune, Boehringer
Ingelheim and GlaxoSmithKline. Ms. Freeman has also served on the
Alliance for Regenerative Medicine (ARM) Cell Therapy Advisory
Committee and has been recognized by Women in Bio as a Female
Pioneer in the Life Sciences. After receiving her Bachelor of
Science in Biology from Cornell University, Ms. Freeman was a
Research Scientist in the Department of Hematology/Medical Oncology
at Weill Cornell Medical Center and later pursued Graduate Studies
at SUNY Upstate Medical Center. Ms. Freeman also received Finance
and Marketing Certificates from the Wharton School of the
University of Pennsylvania.
“It is a privilege to join the Zentalis management team at such
an exciting time in the Company’s history. I look forward to
working with the team to shape and advance the Company’s strategic
priorities,” said Ms. Freeman. “I see tremendous opportunity for
azenosertib to change the therapeutic paradigm in a number of solid
tumor types as it continues to emerge as a promising new
therapeutic for cancer patients.”
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company discovering and developing small molecule
therapeutics targeting fundamental biological pathways of cancers.
Utilizing its Integrated Discovery Engine, the Company is
developing a focused pipeline of potentially best-in-class oncology
candidates, which include azenosertib (ZN-c3), a WEE1 inhibitor for
advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic
malignancies and related disorders, and a heterobifunctional
degrader of BCL-xL for solid and hematological malignancies. The
Company is also leveraging its extensive experience and
capabilities across cancer biology and medicinal chemistry to
advance its research on protein degraders. Zentalis has operations
in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on Twitter at @ZentalisP and on LinkedIn
at www.linkedin.com/company/zentalis-pharmaceuticals.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including statements regarding the
anticipated contribution and value of management team members; our
goal of capitalizing on the azenosertib opportunity; our goals of
advancing azenosertib in ovarian and uterine cancer indications and
expanding to other Cyclin E1 positive tumor types; and the
potential opportunity with and benefits of azenosertib. The terms
“advance,” “expand,” “look forward,” “opportunity,” “promising,”
“seek,” “will,” and similar references are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. These statements are
neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause our
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including,
but not limited to, the following: our limited operating history,
which may make it difficult to evaluate our current business and
predict our future success and viability; we have and expect to
continue to incur significant losses; our need for additional
funding, which may not be available; our plans, including the costs
thereof, of development of any diagnostic tools, if needed; the
outcome of preclinical testing and early trials may not be
predictive of the success of later clinical trials; failure to
identify additional product candidates and develop or commercialize
marketable products; potential unforeseen events during clinical
trials could cause delays or other adverse consequences; risks
relating to the regulatory approval process or ongoing regulatory
obligations; failure to obtain U.S. or international marketing
approval; our product candidates may cause serious adverse side
effects; inability to maintain our collaborations, or the failure
of these collaborations; our reliance on third parties; effects of
significant competition; the possibility of system failures or
security breaches; risks relating to intellectual property; our
ability to attract, retain and motivate qualified personnel, and
risks relating to management transitions; significant costs as a
result of operating as a public company; and the other important
factors discussed under the caption “Risk Factors” in our most
recently filed periodic report on Form 10-K or 10-Q and subsequent
filings with the U.S. Securities and Exchange Commission (SEC) and
our other filings with the SEC. Any such forward-looking statements
represent management’s estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
ZENTALIS® and its associated logos are trademarks of
Zentalis and/or its affiliates. All website addresses and other
links in this press release are for information only and are not
intended to be an active link or to incorporate any website or
other information into this press release.
Contact:Katie Beach Oltsik Evoke
CanaleKatherine.Beach@evokegroup.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024